Phenotype of CD3+ T Cells and Elevated TCRBV+ Fractions in Three Patients Before and in Two Patients Also During IFN-α Therapy
| Patient/Day of IFN-α . | Fraction . | % per CD3+ Cells . | % per CD4+ Cells . | % per CD8+ Cells . |
|---|---|---|---|---|
| A, d 0 | CD4+ | 21 | ||
| CD8+ | 77 | |||
| TCRBV3+ | 25 | 1 | 99 | |
| A, d 1,183 | CD4+ | 46 | ||
| CD8+ | 53 | |||
| TCRBV3+ | 8 | 49 | 51 | |
| G, d 7 | CD4+ | 69 | ||
| CD8+ | 30 | |||
| TCRBV2+ | 13 | 6 | 94 | |
| TCRBV20+ | 7 | 73 | 27 | |
| G, d 463 | CD4+ | 70 | ||
| CD8+ | 22 | |||
| TCRBV2+ | 9 | 25 | 75 | |
| TCRBV20+ | 5 | 84 | 16 | |
| E, d 0 | CD4+ | 20 | ||
| CD8+ | 70 | |||
| TCRBV22+ | 22 | 19 | 78 |
| Patient/Day of IFN-α . | Fraction . | % per CD3+ Cells . | % per CD4+ Cells . | % per CD8+ Cells . |
|---|---|---|---|---|
| A, d 0 | CD4+ | 21 | ||
| CD8+ | 77 | |||
| TCRBV3+ | 25 | 1 | 99 | |
| A, d 1,183 | CD4+ | 46 | ||
| CD8+ | 53 | |||
| TCRBV3+ | 8 | 49 | 51 | |
| G, d 7 | CD4+ | 69 | ||
| CD8+ | 30 | |||
| TCRBV2+ | 13 | 6 | 94 | |
| TCRBV20+ | 7 | 73 | 27 | |
| G, d 463 | CD4+ | 70 | ||
| CD8+ | 22 | |||
| TCRBV2+ | 9 | 25 | 75 | |
| TCRBV20+ | 5 | 84 | 16 | |
| E, d 0 | CD4+ | 20 | ||
| CD8+ | 70 | |||
| TCRBV22+ | 22 | 19 | 78 |